This Week in Endocrinology — Sep 16, 2026

Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning a cluster of major new consensus guidance in diabetes care, the emotional burden of living with diabetes, the diagnostic minefield of primary aldosteronism, and reproductive and musculoskeletal endocrinology. Let's dive in.

We start with guidelines, because three significant consensus documents landed together. The updated 2026 consensus report on managing type 1 diabetes in adults, from the American Diabetes Association and the European Association for the Study of Diabetes, appears in Diabetes Care, led by Holt and colleagues [1]. It builds on the 2021 report, and the centre of gravity has shifted decisively toward technology — automated insulin delivery and continuous glucose monitoring are now woven through the document rather than treated as add-ons. Importantly, it also incorporates disease-modifying interventions to delay progression to stage 3 type 1 diabetes, which means immunotherapy is now part of the mainstream conversation. The scope has widened as well, to include systematic screening for long-term complications and, notably, the management of obesity and cardiovascular risk factors in people with type 1 diabetes — a population where we have historically imported our risk-management habits from type 2 without much evidence. Psychosocial care and structured self-management education remain foundational.

Alongside that, also in Diabetes Care, a joint working group of the International Society for Pediatric and Adolescent Diabetes, the European Association, and the American Diabetes Association has produced the first consensus report of its kind on transitioning young people with diabetes from paediatric to adult services, led by de Beaufort [3]. This is a period with high rates of unplanned healthcare use and increased risk of premature morbidity and mortality, and the group reached consensus on 31 statements covering the whole continuum — pre-transfer preparation, the transfer itself, and post-transfer follow-up. They supplemented the systematic review with global survey data from clinicians, people with diabetes, and caregivers, and put lower-grade evidence through a Delphi process. The practical message is that transition should be a structured, documented local pathway with a named process, not an administrative handover letter. If your service does not have one written down, this document gives you the scaffolding.

The second theme is diabetes distress, and here two papers in Diabetologia speak directly to one another. Speight and colleagues present the 2026 EASD evidence-based clinical practice guideline on assessing and managing diabetes distress in adults with either type of diabetes [2]. It offers eight Good Practice Statements on assessment — routinely discussing emotional wellbeing, using validated tools rather than informal impressions, monitoring over time, collaborative care planning, documenting what you find, and ensuring psychological support is actually available to refer to. On management, the recommendations are conditional: for type 1 diabetes, psychological interventions, continuous glucose monitoring and automated insulin delivery; for type 2 diabetes, psychological, psychoeducational and educational interventions. The guideline is candid that high-quality trials are scarce, particularly outside high-income settings.

That candour is borne out by the commissioned evidence base, published separately in Diabetologia by Schipper and colleagues — a systematic review and meta-analysis of 248 randomised trials covering more than fifty-five thousand participants [10]. Psychological interventions did reduce diabetes distress compared with usual care in both type 1 and type 2 diabetes, but the effect sizes were small and the certainty of evidence was low to very low. Continuous glucose monitoring or intermittently scanned monitoring reduced distress in type 1 diabetes compared with standard fingerstick testing, and this was the one comparison rated moderate certainty. Educational interventions helped in type 2 diabetes, on low-certainty evidence from only three trials. Crucially, most other comparisons — peer support, device-based interventions against active controls, psychoeducation — showed no statistically significant effect, and the majority of included trials carried some concerns or a high risk of bias. So the honest summary for practice is this: ask about distress routinely with a validated tool, because that part is cheap and clearly recommended; offer psychological support and modern glucose technology where you can; but calibrate your expectations about effect size, and don't assume that generic education or peer support alone will shift the emotional burden.

One more diabetes paper bridges technology and outcomes. In the Journal of Clinical Endocrinology and Metabolism, Sabbe and colleagues followed 246 adults with type 1 diabetes at a tertiary centre for five years, asking whether continuous glucose monitoring metrics predict microvascular complications [8]. Across the cohort time in range rose by about eleven points, to roughly sixty percent. The interesting signal was in the direction of change: among patients whose time in range fell by ten points or more, about a third developed a microvascular complication, compared with roughly eight percent of those whose time in range stayed stable. Change in time in range remained independently associated with outcomes after adjustment for age and baseline values, suggesting it carries prognostic information beyond HbA1c. This is observational, single-centre, and the authors are explicit that it needs validation — but it supports a habit many of us already have, of paying attention to a deteriorating trend rather than only to the current download.

Turning to adrenal disease, two papers in the Journal of Clinical Endocrinology and Metabolism tackle the same frustrating problem — how to trust the aldosterone-to-renin ratio. Parasiliti-Caprino and colleagues studied 342 patients at a referral centre for endocrine hypertension who had two valid ratio measurements, of whom just under two thirds ultimately had confirmed primary aldosteronism [4]. Different interpretation strategies gave genuinely different trade-offs. Requiring both measurements to be positive, at a threshold of 49, gave the best balanced accuracy, at just over three quarters, with sensitivity around eighty percent. More useful clinically is the gradient in post-test probability: with two negative results, the probability of primary aldosteronism was about one in five; with two positive results, over eighty percent; and with one positive and one negative, in either order, it sat in the middle at roughly a third. That discordant group is the one you cannot resolve with more ratios — it needs integration with the clinical picture and confirmatory testing.

And the companion debate piece, from Teo, Pamporaki, Lenders and colleagues, asks whether we must withdraw renin-angiotensin-aldosterone-modifying drugs before diagnostic testing at all [5]. The case for withdrawal rests on diagnostic accuracy driving targeted treatment; the case against rests on feasibility, patient safety during a washout, and cost. The authors conclude that the data on either side are limited, and that prospective outcome studies are needed. In the meantime, the honest position is that a positive ratio on interfering medication is still informative, a negative one is less reassuring, and the decision to wash out should be individualised to blood pressure severity and the strength of pre-test suspicion.

Finally, reproductive and musculoskeletal endocrinology. In Diabetes Care, Neven and colleagues report a prospective nested cohort of 3,645 pregnant women with hyperglycaemia risk factors, enrolled within an international trial of gestational diabetes treatment [6]. Polycystic ovary syndrome — which they term polyendocrine metabolic ovarian syndrome — was present in about one in six. After adjustment for age, baseline BMI, ethnicity, parity, smoking and education, it was associated with modestly increased odds of early gestational diabetes, a composite of adverse neonatal outcomes, and admission to a special care nursery or neonatal intensive care, along with slightly earlier birth. There were no interactions with BMI or ethnicity, which is the key point: the risk is independent of obesity, so a slim patient with the syndrome still warrants early screening and closer surveillance. Complementing this, a review in the Journal of Clinical Endocrinology and Metabolism by Knorr and colleagues maps glucose excursions across the whole female reproductive lifespan — puberty, the menstrual cycle, fertility treatment, pregnancy and menopause — and highlights how thin the evidence is outside pregnancy, particularly for type 2 diabetes and for women undergoing ovarian stimulation or taking menopausal hormone therapy [9]. And in the European Journal of Endocrinology, Mazziotti, Minisola and Canalis argue that acromegalic osteoarthropathy should be reframed as a single disorder of pathological musculoskeletal remodelling linking bone fragility, arthropathy, muscle dysfunction and body composition, which often persists after biochemical control [7]. Practically, that means vertebral fracture assessment and functional evaluation, not bone density alone, and long-term multidisciplinary surveillance rather than discharge once the growth hormone axis is normalised.

If you only have time for one paper this week, make it the updated 2026 American Diabetes Association and European Association consensus report on type 1 diabetes in adults [1]. It is the document that will reset the default standard of care in your clinic, from technology thresholds to complication screening to who gets considered for disease-modifying therapy.

Here are the key takeaways from this week in Endocrinology. First, the type 1 diabetes consensus has broadened well beyond glucose — expect to be managing obesity and cardiovascular risk actively in this population, and to be screening systematically for complications. Second, build a written transition pathway for your adolescents; there are now 31 consensus statements telling you what it should contain. Third, screen for diabetes distress with a validated tool as routine practice, but recognise that the interventions we have produce small effects on low-certainty evidence, with continuous glucose monitoring in type 1 diabetes the best-supported option. Fourth, watch the trajectory of time in range, not just the current number — a ten-point fall carried a substantially higher five-year risk of microvascular complications. Fifth, in suspected primary aldosteronism, two concordant aldosterone-to-renin ratios are far more informative than one, and discordant results define an intermediate-probability group you should not over-interpret. And sixth, polycystic ovary syndrome raises pregnancy risk independently of body weight.

That's your roundup for This Week in Endocrinology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.